mwirth-epo/epo-nmt-datasets huggingface dataset:
2.根据权利要求1所述的重组TCR，其中所述重组TCR由置于免疫应答细胞的内源性TRAC基因座和/或TRBC基因座中的表达盒表达。
The recombinant TCR of claim 1, wherein the recombinant TCR is expressed from an expression cassette placed in an endogenous TRAC locus and/or a TRBC locus of an immunoresponsive cell.
3.根据权利要求2所述的重组TCR，其中所述重组TCR表达盒的放置破坏或废除所述免疫应答细胞中包含天然TCRα链和/或天然TCRβ链的TCR的内源性表达。
3.
4.根据权利要求2所述的重组TCR，其中所述重组TCR表达盒的放置防止或消除所述免疫应答细胞中所述重组TCR与天然TCRα链和/或天然TCR β链之间的错配。
The recombinant TCR of claim 2, wherein the placement of the expression cassette (a) disrupts or abolishes the endogenous expression of a TCR comprising a native TCR α chain and/or a native TCR β chain in the immunoresponsive cell; or (b) prevents or eliminates mispairing between the recombinant TCR and a native TCR α chain and/or a native TCR β chain in the immunoresponsive cell.
5.根据权利要求1-4中任一项所述的重组TCR，其中所述恒定结构域能够与另一恒定结构域形成同二聚体或异二聚体。
The recombinant TCR of claim 1, wherein the constant domain is capable of forming a homodimer or a heterodimer with another constant domain.
6.根据权利要求1-5中任一项所述的重组TCR，其中所述抗原结合链能够与CD3ζ多肽缔合。
The recombinant TCR of claim 1, wherein the antigen binding chain is capable of associating with a CD3ζ polypeptide.
7.根据权利要求6所述的重组TCR，其中所述抗原结合链在与抗原结合后能够激活与所述抗原结合链缔合的所述CD3ζ多肽。
The recombinant TCR of claim 5, wherein the antigen binding chain, upon binding to an antigen, is capable of activating the CD3ζ polypeptide associated to the antigen binding chain.
8.根据权利要求7所述的重组TCR，其中所述CD3ζ多肽的激活能够激活免疫应答细胞。
The recombinant TCR of claim 6, wherein activation of the CD3ζ polypeptide is capable of activating an immunoresponsive cell.
9.根据权利要求6所述的重组TCR，其中所述CD3ζ多肽是内源性的并且整合在天然CD3复合物中。
The recombinant TCR of claim 5, wherein the CD3ζ polypeptide is endogenous and integrated in the native CD3 complex.
10.根据权利要求6所述的重组TCR，其中所述CD3ζ多肽是外源性的并且任选地与选自CD28多肽、4-1BB多肽、OX40多肽、ICOS多肽、DAP-10多肽、及其任意组合的共刺激分子整合。
The recombinant TCR of claim 5, wherein the CD3ζ polypeptide is exogenous and optionally integrated with a co-stimulatory molecule selected from the group consisting of a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide and any combination thereof.
11.根据权利要求1-10中任一项所述的重组TCR，其中所述抗原结合链还包含共刺激区，其中所述重组TCR在与抗原结合后能够刺激免疫应答细胞。
The recombinant TCR of claim 1, wherein the antigen binding chain further comprises a co-stimulatory region, wherein the recombinant TCR, upon binding to an antigen, is capable of stimulating an immunoresponsive cell.
12.根据权利要求11所述的重组TCR，其中所述共刺激区包含选自CD28多肽、4-1BB多肽、OX40多肽、ICOS多肽、DAP-10多肽、及其任意组合的共刺激分子。
The recombinant TCR of claim 10, wherein the co-stimulatory region comprises a co-stimulatory molecule selected from the group consisting of a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide and any combination thereof.
13.根据权利要求12所述的重组TCR，其中所述共刺激区包含CD28多肽。
The recombinant TCR of claim 11, wherein the co-stimulatory region comprises a CD28 polypeptide.
14.根据权利要求1-13中任一项所述的重组TCR，其中所述重组TCR能够与CD3复合物整合并且提供HLA-非依赖性抗原识别。
The recombinant TCR of claim 1, wherein the recombinant TCR is capable of integrating with a CD3ζ complex and providing HLA-independent antigen recognition.
15.根据权利要求14所述的重组TCR，其中所述CD3复合物是内源性的。
The recombinant TCR of claim 13, wherein the CD3ζ complex is endogenous.
16.根据权利要求15所述的重组TCR，其中所述重组TCR替代CD3/TCR复合物中的内源性TCR。
The recombinant TCR of claim 14, wherein the recombinant TCR replaces an endogenous TCR in a CD3/TCR complex.
17.根据权利要求1-16中任一项所述的重组TCR，其中所述细胞外抗原结合结构域能够与另一细胞外抗原结合结构域二聚化。
The recombinant TCR of claim 1, wherein the extracellular antigen-binding domain is capable of dimerizing with another extracellular antigen-binding domain.
18.根据权利要求1-17中任一项所述的重组TCR，其中所述细胞外抗原结合结构域包含细胞表面受体的配体，细胞表面配体的受体，抗体或其片段的抗原结合部分，或TCR的抗原结合部分。
The recombinant TCR of claim 1, wherein the extracellular antigen-binding domain comprises a ligand for a cell-surface receptor, a receptor for a cell surface ligand, an antigen binding portion of an antibody, or an antigen binding portion of a TCR.
19.根据权利要求1-18中任一项所述的重组TCR，其中所述细胞外抗原结合结构域包含一个或两个免疫球蛋白可变区。
The recombinant TCR of claim 1, wherein the extracellular antigen-binding domain comprises one or two immunoglobulin variable region(s).
20.根据权利要求18所述的重组TCR，其中所述细胞外抗原结合结构域包含抗体的重链可变区(VH)。
The recombinant TCR of claim 17, wherein the extracellular antigen-binding domain comprises a heavy chain variable region (VH) of an antibody, and/or a light chain variable region (VL) of an antibody.
21.根据权利要求18所述的重组TCR，其中所述细胞外抗原结合结构域包含抗体的轻链可变区(VL)。
20.
22.根据权利要求18所述的重组TCR，其中所述细胞外抗原结合结构域能够与另一细胞外抗原结合结构域二聚化。
The recombinant TCR of claim 1, wherein the extracellular antigen-binding domain is capable of dimerizing with another extracellular antigen-binding domain.
23.根据权利要求20所述的重组TCR，其中所述细胞外抗原结合结构域包含抗体的VH，其中所述VH能够与包含所述抗体的VL的另一细胞外抗原结合结构域二聚化并且形成可变片段(Fv)。
The recombinant TCR of claim 20, wherein the extracellular antigen-binding domain comprises (a) a VHof an antibody, wherein the VHis capable of dimerizing with another extracellular antigen-binding domain comprising a VLof the antibody and form a fragment variable (Fv); and/or a VLof an antibody, wherein the VLis capable of dimerizing with another extracellular antigen-binding domain comprising a VHof the antibody and form a fragment variable (Fv).
24.根据权利要求21所述的重组TCR，其中所述细胞外抗原结合结构域包含抗体的VL，其中所述VL能够与包含所述抗体的VH的另一细胞外抗原结合结构域二聚化并且形成可变片段(Fv)。
22.
25.根据权利要求1至24中任一项所述的重组TCR，其中所述重组TCR与肿瘤抗原结合。
The recombinant TCR of claim 1, wherein the recombinant TCR binds to a tumor antigen.
26.根据权利要求25所述的重组TCR，其中所述肿瘤抗原选自CD19、MUC16、MUC1、CA1X、CEA、CD8、CD7、CD10、CD20、CD22、CD30、CLL1、CD33、CD34、CD38、CD41、CD44、CD49f、CD56、CD74、CD133、CD138、EGP-2、EGP-40、EpCAM、erb-B2,3,4、FBP、胎儿乙酰胆碱受体、叶酸受体-a、GD2、GD3、HER-2、hTERT、IL-13R-a2、K-轻链、KDR、LeY、L1细胞粘附分子、MAGE-A1、间皮素、ERBB2、MAGEA3、p53、MART1、GP100、蛋白酶3(PR1)、酪氨酸酶、存活蛋白、hTERT、EphA2、NKG2D配体、NY-ES0-1、癌胚抗原(h5T4)、PSCA、PSMA、ROR1、TAG-72、VEGF-R2、WT-1、BCMA、CD123、CD44V6、NKCS1、EGF1R、EGFR-VIII、和CD99、CD70、ADGRE2、CCR1、LILRB2、LILRB4、PRAME和ERBB。
The recombinant TCR of claim 22, wherein the tumor antigen is selected from the group consisting of CD19, MUC16, MUC1, CA1X, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2,3,4, FBP, Fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13R-a2, K-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, Mesothelin, ERBB2, MAGEA3, p53, MART 1, GP100, Proteinase3 (PR1), Tyrosinase, Survivin, hTERT, EphA2, NKG2D ligands, NY-ES0-1, oncofetal antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII, and CD99, CD70, ADGRE2, CCR1, LILRB2, LILRB4, PRAME, and ERBB.
27.根据权利要求25或26所述的重组TCR，其中所述肿瘤抗原是CD19。
The recombinant TCR of claim 23, wherein the tumor antigen is CD19.
28.根据权利要求1-27中任一项所述的重组TCR，其中所述重组TCR显示出比靶向相同抗原的CAR更高的抗原敏感性。
25.
29.根据权利要求1-28中任一项所述的重组TCR，其中所述重组TCR在与肿瘤细胞表面上具有低密度的抗原结合时能够诱导免疫应答。
The recombinant TCR of claim 1, wherein the recombinant TCR exhibits greater antigen sensitivity than a CAR targeting the same antigen, and/or is capable of inducing an immune response when binds to an antigen that has a low density on the surface of a tumor cell.
30.根据权利要求1-28中任一项所述的重组TCR，其中在所述细胞表面上具有低密度的所述抗原具有每个细胞小于约10,000个分子的密度。
The recombinant TCR of claim 1, wherein the antigen that has a low density on the cell surface has a density of less than about 10,000 molecules per cell.
31.一种免疫应答细胞，其包含权利要求1-30中任一项所述的重组TCR。
27.
32.根据权利要求31所述的免疫应答细胞，其中所述重组TCR的至少一条抗原结合链的表达盒置于所述免疫应答细胞的内源性基因座处。
An immunoresponsive cell comprising a recombinant TCR that comprises an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC peptide and/or a native or modified TRBC peptide.
33.根据权利要求32所述的免疫应答细胞，其中所述重组TCR的两条抗原结合链的表达盒置于所述免疫应答细胞的内源性基因座处，其中所述两条抗原结合链能够二聚化。
The immunoresponsive cell of claim 27, wherein at least one antigen binding chain of the recombinant TCR is expressed from an expression cassette placed at an endogenous gene locus of the immunoresponsive cell, optionally wherein two antigen binding chains of the recombinant TCR are expressed from expression cassettes placed at the endogenous gene locus of the immunoresponsive cell, wherein the two antigen binding chains are capable of dimerization.
34.根据权利要求31-33中任一项所述的免疫应答细胞，其中所述内源性基因座是CD3δ基因座、CD3ε基因座、CD247基因座、B2M基因座、TRAC基因座、TRBC基因座、TRDC基因座和/或TRGC基因座。
The immunoresponsive cell of claim 28, wherein the endogenous gene locus is a CD3δ locus, a CD3ε locus, a CD247 locus, a B2M locus, a TRAC locus, a TRBC locus, a TRDC locus and/or a TRGC locus.
35.根据权利要求34所述的免疫应答细胞，其中所述内源性基因座是TRAC基因座和/或TRBC基因座。
The immunoresponsive cell of claim 29, wherein the endogenous gene locus is a TRAC locus and/or a TRBC locus.
36.根据权利要求35所述的免疫应答细胞，其中所述重组TCR的表达盒的放置破坏或废除所述免疫应答细胞中包含天然TCR α链和/或天然TCR β链的TCR的内源性表达，从而防止或消除所述免疫应答细胞中所述重组TCR与天然TCR α链和/或天然TCRβ链之间的错配。
The immunoresponsive cell of claim 28, wherein the placement of the expression cassette of the recombinant TCR disrupts or abolishes the endogenous expression of a TCR comprising a native TCR α chain and/or a native TCR β chain in the immunoresponsive cell, whereby preventing or eliminating mispairing between the recombinant TCR and a native TCR α chain and/or a native TCR β chain in the immunoresponsive cell.
37.根据权利要求32-36中任一项所述的免疫应答细胞，其中所述内源性基因座包含修饰的转录终止子区。
The immunoresponsive cell of claim 28, wherein the endogenous gene locus comprises a modified transcription terminator region.
38.根据权利要求37所述的免疫应答细胞，其中所述修饰的转录终止子区包含选自TK转录终止子、GCSF转录终止子、TCRA转录终止子、HBB转录终止子、牛生长激素转录终止子、SV40转录终止子和P2A元件的基因组元件。
The immunoresponsive cell of claim 32, wherein the modified transcription terminator region comprises a genomic element selected from the group consisting of a TK transcription terminator, a GCSF transcription terminator, a TCRA transcription terminator, an HBB transcription terminator, a bovine growth hormone transcription terminator, an SV40 transcription terminator, and a P2A element.
39.根据权利要求32-38中任一项所述的免疫应答细胞，其中当细胞中一个内源性T细胞受体基因座被修饰以表达所述重组TCR的至少一条抗原结合链时，所述细胞中的一个或多个其它内源性T细胞受体基因座被修饰以消除内源性TCR链的表达。
The immunoresponsive cell of claim 28, wherein when one endogenous T cell receptor locus in a cell is modified to express the at least one antigen binding chain of the recombinant TCR, at least one additional endogenous T cell receptor locus in the cell is modified to eliminate the expression of an endogenous TCR chain.
40.根据权利要求39所述的免疫应答细胞，其中所述一个或多个其它内源性T细胞受体基因座被进一步修饰以表达目的基因。
35.
41.根据权利要求40所述的免疫应答细胞，其中所述目的基因是抗肿瘤细胞因子、共刺激分子配体、追踪基因或自杀基因。
The immunoresponsive cell of claim 34, wherein the at least one additional endogenous T cell receptor locus is further modified to express a gene of interest, optionally wherein the gene of interest is an anti-tumor cytokine, a co-stimulatory molecule ligand, a tracking gene or a suicide gene.
42.根据权利要求31-41中任一项所述的免疫应答细胞，其中所述细胞选自T细胞、细胞毒性T淋巴细胞(CTL)、调节性T细胞、天然杀伤性T(NKT)细胞、人胚胎干细胞、和可从中分化出淋巴样细胞的多能干细胞。
The immunoresponsive cell of claim 27, wherein the immunoresponsive cell is selected from the group consisting of a T cell, a human embryonic stem cell, and a pluripotent stem cell from which lymphoid cells may be differentiated.
43.根据权利要求31-42中任一项所述的免疫应答细胞，其中所述免疫应答细胞是自体的。
The immunoresponsive cell of claim 36, wherein the immunoresponsive cell is a T cell.
44.根据权利要求31-43中任一项所述的免疫应答细胞，其还包含至少一种外源性共刺激配体。
38.
45.根据权利要求44所述的免疫应答细胞，其中所述外源性共刺激配体选自CD80、CD86、41BBL、CD275、CD40L、OX40L、及其任意组合。
The immunoresponsive cell of claim 37, wherein the T cell is selected from the group consisting of a cytotoxic T lymphocyte (CTL), a regulatory T cell, and a Natural Killer T (NKT) cell.
46.根据权利要求44或45所述的免疫应答细胞，其中所述细胞还包含一种外源性共刺激配体或由其组成。
The immunoresponsive cell of claim 27, further comprising at least one exogenous co-stimulatory ligand.
47.根据权利要求46所述的免疫应答细胞，其中所述一种外源性共刺激配体是CD80或4-1BBL。
The immunoresponsive cell of claim 39, wherein the exogenous co-stimulatory ligand is selected from the group consisting of CD80, CD86, 41BBL, CD275, CD40L, OX40L, and combinations thereof.
48.根据权利要求44或45所述的免疫应答细胞，其中所述细胞还包含两种外源性共刺激配体或由其组成。
41.
49.根据权利要求48所述的免疫应答细胞，其中所述两种外源性共刺激配体是CD80和4-1BBL。
The immunoresponsive cell of claim 39, wherein (a) the cell further comprises or consists of one exogenous co-stimulatory ligand, optionally wherein the one exogenous co-stimulatory ligand is CD80 or 4-1BBL; or (b) the cell further comprises or consists of two exogenous co-stimulatory ligands, optionally wherein the two exogenous co-stimulatory ligands are CD80 and 4-1BBL.
50.根据权利要求31-49中任一项所述的免疫应答细胞，其还包含至少一种嵌合共刺激受体(CCR)。
The immunoresponsive cell of claim 27, further comprising at least one chimeric costimulatory receptor (CCR).
51.根据权利要求50所述的免疫应答细胞，其中所述CCR包含选自CD28多肽、4-1BB多肽、OX40多肽、ICOS多肽、DAP-10多肽、及其任意组合的共刺激分子。
The immunoresponsive cell of claim 42, wherein the CCR comprises a co-stimulatory molecule selected from the group consisting of a CD28 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, an ICOS polypeptide, a DAP-10 polypeptide, and combinations thereof.
52.一种药物组合物，其包含有效量的权利要求31-47中任一项所述的免疫应答细胞和药学上可接受的赋形剂。
A pharmaceutical composition comprising an effective amount of an immunoresponsive cell of claim 27 and a pharmaceutically acceptable excipient, optionally wherein the pharmaceutical composition is for treating a neoplasm.
53.根据权利要求52所述的药物组合物，其用于治疗肿瘤。
45.
55.一种治疗或预防肿瘤的方法，所述方法包括向所述受试者施用有效量的权利要求31-51中任一项所述的免疫应答细胞或权利要求52或53所述的药物组合物。
A method of reducing tumor burden in a subject, and/or treating or preventing a neoplasm in a subject, and/or lengthening survival of a subject having a neoplasm, the method comprising administering to the subject an effective amount of the immunoresponsive cells of claim 27.
57.根据权利要求55或56所述的方法，其中所述肿瘤是B细胞白血病、多发性骨髓瘤、急性淋巴母细胞性白血病(ALL)、慢性淋巴细胞性白血病或非霍奇金氏淋巴瘤，并且所述重组TCR结合CD19。
46.
58.根据权利要求55或56所述的方法，其中所述肿瘤是B细胞白血病、多发性骨髓瘤、急性淋巴母细胞性白血病(ALL)、急性髓细胞性白血病(AML)、慢性淋巴细胞性白血病、或非霍奇金氏淋巴瘤，并且所述重组TCR结合BCMA、ADGRE2、CCR1、CD22、CD70、或其组合。
A method for producing an antigen-specific immunoresponsive cell, the method comprising introducing into an immunoresponsive cell a nucleic acid molecule encoding a recombinant TCR comprising an antigen binding chain that comprises an extracellular antigen-binding domain and a constant domain, wherein the recombinant TCR binds to an antigen in an HLA-independent manner, wherein the constant domain comprises a native or modified TRAC polypeptide and/or a native or modified TRBC polypeptide.
59.根据权利要求55-58中任一项所述的方法，其中所述肿瘤是CD19+ALL。
47.
60.一种产生抗原特异性免疫应答细胞的方法，所述方法包括将编码权利要求1-30中任一项所述的重组TCR的核酸序列导入免疫应答细胞。
The method of claim 46, wherein at least one antigen binding chain of the recombinant TCR is expressed from an expression cassette placed at an endogenous gene locus of the immunoresponsive cell, optionally wherein two antigen binding chains of the recombinant TCR are expressed from expression cassettes placed at the endogenous gene locus of the immunoresponsive cell, wherein the two antigen binding chains are capable of dimerization.
61.根据权利要求60所述的方法，其中所述核酸序列包含在载体中。
48.
64.根据权利要求62或63所述的方法，其中所述内源性基因座是CD3δ基因座、CD3ε基因座、CD247基因座、B2M基因座、TRAC基因座、TRBC基因座、TRDC基因座和/或TRGC基因座。
The method of claim 47, wherein the endogenous gene locus is a CD3δ locus, a CD3ε locus, a CD247locus, a B2M locus, a TRAC locus, a TRBC locus, a TRDC locus and/or a TRGC locus, optionally wherein wherein the endogenous gene locus is a TRAC locus and/or a TRBC locus.
65.根据权利要求64所述的方法，其中所述内源性基因座是TRAC基因座和/或TRBC基因座。
49.
68.根据权利要求67所述的方法，其中所述修饰的转录终止子区包含选自TK转录终止子、GCSF转录终止子、TCRA转录终止子、HBB转录终止子、牛生长激素转录终止子、SV40转录终止子和P2A元件的基因组元件。
The method of claim 47, wherein the endogenous gene locus comprises a modified transcription terminator region, optionally wherein the modified transcription terminator region comprises a genomic element selected from the group consisting of a TK transcription terminator, a GCSF transcription terminator, a TCRA transcription terminator, a HBB transcription terminator, a bovine growth hormone transcription terminator, an SV40 transcription terminator, and a P2A element.
69.根据权利要求62-68中任一项所述的方法，其中当细胞中一个内源性T细胞受体基因座被修饰以表达所述重组TCR的至少一条抗原结合链时，所述细胞中的一个或多个其它内源性T细胞受体基因座被修饰以消除内源性TCR链的表达。
The method of claim 47, wherein when one endogenous T cell receptor locus in a cell is modified to express the at least one antigen binding chain of the recombinant TCR, at least one additional endogenous T cell receptor locus in the cell is modified to eliminate the expression of an endogenous TCR chain, optionally wherein the at least one additional endogenous T cell receptor locus is further modified to express a gene of interest, optionally wherein the gene of interest is an anti-tumor cytokine, a co-stimulatory molecule ligand, a tracking gene or a suicide gene.
72.一种延长患有肿瘤的受试者的存活的方法，所述方法包括向所述受试者施用有效量的权利要求31-51中任一项所述的免疫应答细胞或权利要求52或53所述的药物组合物。
51.
73.一种核苷酸，其编码权利要求1-30中任一项所述的重组TCR。
A nucleotide acid molecule encoding a recombinant TCR of claim 1.
75.根据权利要求74所述的核酸组合物，其中所述核酸序列包含在载体中。
52.
76.一种载体，其包含权利要求74或75所述的核酸组合物。
A vector comprising the nucleic acid molecule of claim 51.
77.一种试剂盒，其包含权利要求1-30中任一项所述的重组TCR、权利要求31-51中任一项所述的免疫应答细胞、权利要求52或53所述的药物组合物、权利要求74或75所述的核酸组合物、或权利要求76所述的载体。
53.
78.根据权利要求77所述的试剂盒，其中所述试剂盒还包含用于治疗和/或预防肿瘤、病原体感染、自身免疫性疾病或同种异体移植的书面说明书。
A kit comprising a recombinant TCR of claim 1, optionally wherein the kit further comprises written instructions for treating and/or preventing a neoplasm, a pathogen infection, an autoimmune disorder, or an allogeneic transplant.
(b)中的箭头XIIa-XIIa方向的截面图)，图12的
Referring to FIG. 11, a main circuit MOSFET module package 101 includes package terminals 102 (three package terminals in the illustrated example).
(b)是示出其电路基板的侧截面图(图12的
Specifically, the pattern wiring 104 surrounds the axis of the conduction direction of the main current (which is the axial direction of each package terminal 102, which has a cylindrical shape).
(a)中的箭头XIIb-XIIb方向的截面图)。
FIG. 12A is a plan view of a circuit substrate including the transformer (a cross-sectional view taken along arrow XIIa-XIIa illustrated in FIG. 12B ), and FIG. 12B is a side cross-sectional view of the circuit substrate (a cross-sectional view taken along arrow XIIb-XIIb illustrated in FIG. 12A ).
在该图12中，在电路基板103上布线有主电流通电的主电路图案布线105，并设置成在以其通电方向为轴的绕轴包围的配置中环状磁芯106贯通电路基板103。
Referring to FIG. 12, a main circuit pattern wiring 105, through which the main current is conducted, is wired on the circuit substrate 103.
并且，在以其磁芯106的通磁方向(即，环状的磁芯106的周向)为轴的绕轴包围的配置中在电路基板103的表面上布线有检测用图案布线107。
A detection pattern wiring 107 is wired on the surface of the circuit substrate 103 and surrounds the axis of the magnetization direction of the magnetic core 106 (that is, the circumferential direction of the ring-shaped magnetic core 106).
这些主电路图案布线105、磁芯106和检测用图案布线107的组合作为变压器来发挥功能。
A combination of the main circuit pattern wiring 105, the magnetic core 106, and the detection pattern wiring 107 serves as a transformer.
此外，检测用图案布线107除了如图示那样在与主电路图案布线105相同的一侧的电路基板103的表面上布线以外，也可以布线于与主电路图案布线105相反的一侧的电路基板103的表面上(省略图示)。
Otherwise, the detection pattern wiring 107 may be wired on the surface of the circuit substrate 103 opposite to the main circuit pattern wiring 105 (this configuration is not illustrated).
即使如此以变压器来安装通电检测部7，也不依赖于主电路MOSFET模块封装101的内部布线布局而能够廉价地安装稳定的主电流的增减变化状态的检测功能。
This configuration as well ensures that a stable function of detecting the increase-decrease change state of the main current is implemented at a lower price, regardless of the wiring layout in the main circuit MOSFET module package 101.
作为上述实施方式的驱动电路1的应用例，例如存在将直流电力PWM电力转换为预定频率的交流电力，并将这些作为驱动电力而供电给马达(旋转型，直动型)的马达控制装置等。
An example application of the driving circuit 1 according to the embodiment is a motor control apparatus that PWM-converts DC power into AC power of a predetermined frequency and feeds the AC power, as driving power, to a motor (rotary type or linear motion type).
以下，对该马达控制装置的构成例进行说明。
An example configuration of this motor control apparatus will be described below.
使用图13，对本实施方式涉及的马达控制装置整体的电路结构进行说明。
By referring to FIG. 13, a circuit configuration of a motor control apparatus according to this embodiment as a whole will be described.
如图13所示，马达控制装置200包括：转换器202，与三相交流电源201连接；以及逆变器205，与马达203连接且经由直流母线204而也与转换器202连接。
As illustrated in FIG. 13, the motor control apparatus 200 includes: a converter 202, which is connected to a three-phase AC power source 201; and an inverter 205, which is connected to a motor 203 and also connected to the converter 202 via the DC bus lines 204.
转换器202具备整流部211和平滑电容器212。
The converter 202 includes a rectifier 211 and a smoothing capacitor 212.
整流部211是由六个二极管213构成的二极管桥，对来自三相交流电源201的交流电力进行全波整流并输出到直流母线204。
With this configuration, the rectifier 211 full-wave rectifies AC power from the three-phase AC power source 201 and outputs the resulting DC power to the DC bus lines 204.
平滑电容器212以经过直流母线204之间的方式连接，对由上述整流部211进行了全波整流的直流电力进行平滑。
The smoothing capacitor 212 is extends between and is connected to the DC bus lines 204, and smoothens the DC power obtained by the full-wave rectification performed at the rectifier 211.
通过以上的结构，转换器202对从三相交流电源201供给的交流电力进行整流、平滑并转换为直流电力，向由正极侧的P线和负极侧的N线两根一组构成的直流母线204输出直流电力。
With this configuration, the converter 202 rectifies and smoothens AC power supplied from the three-phase AC power source 201, thereby converting the AC power into DC power, and outputs the DC power to the DC bus lines 204, which are a pair of a positive electrode P line and a negative electrode N line.
逆变器205具有桥接电路221、上述实施方式的驱动电路1、控制电源223、控制电路224和I/O 225。
The inverter 205 includes a bridge circuit 221, the driving circuit 1 according to the embodiment, a control power source 223, a control circuit 224, and an I/O 225.
桥接电路221是对由该例子的上述主电路MOSFET 100的半导体元件构成的六个臂开关元件100进行桥连接的器件。
The bridge circuit 221 is a device in which six arm switching elements 100, each of which is implemented by the semiconductor element of the main circuit MOSFET 100, are bridge-connected to each other.
详细地讲，将该例子的主电路MOSFET 100串联连接两个并设为一组，针对上述直流母线204并列连接三组。
Specifically, a pair of the main circuit MOSFETs 100 are connected in series to each other, and three such pairs are connected in parallel to the DC bus lines 204.
其中，以下，将与直流母线204的正极侧(P线侧)连接的主电路MOSFET 100称为上臂开关元件100U，并将与负极侧(N线侧)连接的主电路MOSFET 100称为下臂开关元件100D。
Among the main circuit MOSFETs 100, those main circuit MOSFETs 100 connected to the positive electrode side (P line side) DC bus line 204 will be referred to as upper arm switching elements 100U, and those main circuit MOSFETs 100 connected to the negative electrode side (N line side) will be referred to as lower arm switching elements 100D.
三组的每一个中上臂开关元件100U与下臂开关元件100D之间的中间点与各相对应地连接到马达203。
The intermediate points of the three pairs of the upper arm switching elements 100U and the lower arm switching elements 100D correspond to different phases and are connected to the motor 203.
各臂开关元件100通过用驱动电路1控制各自的栅极电压(控制电压)，对其导通状态(ON状态)和切断状态(OFF状态)(即，打开、关闭)进行切换。
The gate voltage (control voltage) of each arm switching element 100 is controlled by the driving circuit 1, and each arm switching element 100 is thus switched between conduction state (ON state) and non-conduction state (OFF state) (that is, between turn-ON and turn-OFF).
驱动电路1基于从后述的控制电路24输入的控制信号，针对桥接电路221的各臂开关元件100控制各自的栅极电压(控制电压)，由此切换其ON状态和OFF状态(即，打开、关闭)。
Based on a control signal input from a control circuit 24, described later, the driving circuit 1 controls the gate voltage (control voltage) of each arm switching element 100 of the bridge circuit 221, thereby switching each arm switching element 100 between ON state and OFF state (that is, between turn-ON and turn-OFF).
此外，驱动电路1以与桥接电路221中的六个臂开关元件100(主电路MOSFET 100)分别独立地对应的方式设置，并分别与各栅极端子Gm和源极端子Sm连接，但在该图13中为了避免图示的烦杂，仅仅示出一个驱动电路1。
It is to be noted that the driving circuit 1 is dedicated to one of the six arm switching elements 100 (main circuit MOSFETs 100) of the bridge circuit 221, that is, one driving circuit 1 is connected to one gate terminal Gm and one source terminal Sm.
控制电路224(控制部)由执行电力控制用软件的CPU(central processing unit，中央处理器)等构成，基于从未图示的上级控制装置经由I/O 225或未图示的信号输入电路等输入的马达控制指令，向各驱动电路1输出控制信号以使得向马达203供给期望的电力。
The control circuit 224 (control device) is made up of a CPU and related devices for executing power control software, and receives a motor control command input from an upper-level control apparatus, not illustrated, through the I/O 225 and/or a signal input circuit, not illustrated.